American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Investing

Will the falling Hims & Hers stock price recover in 2025?

by admin December 23, 2024
December 23, 2024
Will the falling Hims & Hers stock price recover in 2025?

Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped by almost 200% this year, while other companies in the industry like CVS Health and Walgreens Boots Alliance and CVS Health, plunged. So, will the stock have more upside in 2025?

HIMS stock fell after a key FDA ruling

One reason why the Hims & Hers stock price surged has been its entry into the weight loss industry, where it offers quality drugs at a lower cost. 

This business may be under pressure soon, which explains why the stock has crashed by more than 25% from its highest level this year. 

In a statement last week, the Food and Drug Administration (FDA) warned that it was concerned about many weight drugs being sold in the market. In particular, it expressed concerns about compounded drugs, which it said were not approved. 

The FDA noted that it had received adverse events related with compounded semaglutide and tripeptide. Therefore, it is likely that Hims & Hers business will be affected because the weight loss segment is one of its fastest-growing segments. 

The company is seeing strong growth

Hims & Hers stock price surged this year as its business continued doing well because of its large total addressable market. As we have written before, its top markets like weight loss, hair loss, anxiety, and sexual health have a large total addressable market. For example, a report by Oxford noted that over 25% of men in the United States had an erectile dysfunction problem.

Estimates are that millions of Americans have weight issues. According to the CDC, about 9.4% of all Americans had an obesity problem. Also, more people are now more comfortable buying these drugs online, which was not the case a few years ago.

These trends explain why the Hims stock price has done well in the past few years. Its annual revenue stood at just $82.6 million in 2019, making it a fairly small company. Recently, however, its revenue has soared, hitting over $872 million in 2023 and $1.2 billion in the trailing twelve months. 

The most recent results showed that the Hims & Hers revenue jumped by 77% YoY to over $401.6 million. Analysts expect that this growth is just starting, with the current quarter’s revenue rising by 90% to over $469 million. 

The average estimate is that Hims & Hers annual revenue will get to $1.45 billion this year, followed by $2.03 billion in 2026. This trend makes it one of the fastest-growing companies in the healthcare industry.

Hims & Hers is seeing profitable growth. The average estimate is that its EPS will be 22 cents in this quarter, up from $0.05 a year ago. Its annual EPS will move to 8 cents this year, followed by 93 cents in the following year. This growth will help the company justify its high valuation, with its market cap standing at over $5.7 billion today.

Hims & Hers stock price analysis

The daily chart shows that the HIMS share price peaked at $35 in November. As we predicted, it erased some of those gains after the FDA ruling.

The stock’s retreat has seen it retest the important support level at $25.75, its highest swing on June 17. This pattern is known as a break and retest, and is one of the most bullish continuation signs.

The stock has found support at the 50-day Exponential Moving Average. Therefore, there are odds that the stock will bounce back soon and retest the important resistance point at $35, the year-to-date high. A drop below the support at $22 will invalidate the bullish view.

The post Will the falling Hims & Hers stock price recover in 2025? appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
USD/CAD forecast: here’s why the Canadian dollar has crashed
next post
UK economy stagnates as revised GDP figures show no growth in Q3

Related Posts

USD/TRY forecast: to rise to 40 amid Fed...

December 28, 2024

Lodgement of Bidder’s Statement

April 30, 2024

Ethereum price prediction: is ETH a good buy...

February 2, 2025

Top 3 ways to boost the languishing Pi...

May 27, 2025

Very bad news for the popular SCHD ETF

November 21, 2024

EUR/CHF forecast ahead of ECB and SNB rate...

December 9, 2024

EUR/GBP and GBP/USD outlooks: why is the pound...

January 9, 2025

Morningstar stock price dived: is it still overvalued?

January 9, 2025

Yalgoo Fieldwork Commences Over Main Target Areas

May 21, 2024

Cleantech Market Update: Q1 2024 in Review

April 25, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • How Donald Trump’s immigration crackdown may tank the labor market

      August 4, 2025
    • Trump’s tariff threat looms over India’s Russian oil deals

      August 4, 2025
    • Trump moves nuclear submarines near Russia: what triggered the move and what’s ahead

      August 3, 2025
    • BOE rate cuts offer little relief as UK households face mounting financial strain

      August 3, 2025
    • Retail investors shift focus to Europe as US valuations stretch

      August 3, 2025

    Categories

    • Business (3,583)
    • Investing (2,703)
    • Latest News (2,031)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved